PubMed Health⌕ Search

Biomedical subjects

M Gallet

Publications and source records attributed to M Gallet.

At least 19 recordsLinked to original sources

Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases?

BACKGROUND: Genetic testing can determine those at risk for hereditary haemochromatosis (HH) caused by HFE mutations before the onset of symptoms. However, there is no optimum screening strategy, mainly owing to the variable penetrance in those who are homozygous for the HFE Cys282Tyr (C282Y) mutation. The objective of this study was to identify the majority of individuals at serious risk of developing HFE haemochromatosis before they developed life threatening complications. METHODS: We first estimated the therapeutic penetrance of the C282Y mutation in people living in la Somme, France, using genetic, demographic, biochemical, and follow up data. We examined the benefits of neonatal screening on the basis of increased risk to relatives of newborns carrying one or two copies of the C282Y mutation. Between 1999 and 2002, we screened 7038 newborns from two maternity hospitals in the north of France for the C282Y and His63Asp (H63D) mutations in the HFE gene, using bloodspots collected on Guthrie cards. Family studies and genetic counselling were undertaken, based on the results of the baby's genotype. FINDINGS: In la Somme, we found that 24% of the adults homozygous for the C282Y mutation required at least 5 g iron to be removed to restore normal iron parameters (that is, the therapeutic penetrance). In the reverse cascade screening study, we identified 19 C282Y homozygotes (1/370), 491 heterozygotes (1/14) and 166 compound heterozygotes (1/42) in 7038 newborns tested. The reverse cascade screening strategy resulted in 80 adults being screened for both mutations. We identified 10 previously unknown C282Y homozygotes of whom six (four men and two women) required venesection. Acceptance of neonatal screening was high; parents understood the risks of having HH and the benefits of early detection, but a number of parents were reluctant to take the test themselves. Neonatal screening for HH is straightforward. Reverse cascade screening increased the efficiency of detecting affected adults with undiagnosed haemochromatosis. This strategy allows almost complete coverage for HH and could be a model for efficient screening for other late onset genetic diseases.

Adult↗

[Informed consent, what information is left after a therapeutic trial?].

In order to evaluate the outcome of information given to patients included in a therapeutic trial after having signed a consent form, 77 patients (68 men, 9 women with an average age of 57.9 years) included in the IMPACT study (multicenter, randomised, double-blind protocol, the main objective of which was to assess the antiarrhythmic effect of oral administration of delayed action mexiletine in patients with a recent myocardial infarction), answered a questionnaire of 85 items. The quantity and degree of comprehension of the recalled information at the end of the trial were appreciated from the replies to 13 questions based on the definition or understanding of the most important details of the consent form and on a comprehension score with a maximum value of 14 points. The global quantity of information recalled after an interval ranging from 5 to 21 months was estimated at 60% of the information provided but the recall was not uniform according to the different elements of the consent form: the aim of the study, the concept of placebo, the nature of the active treatment, the randomisation and possible side effects were only correctly apprehended by 40 to 50% of patients: the type of patient included, the duration of the trial, the content of the gelules, the division between treatment/placebo and the concept of double-blind were known to 50 to 75% of participants: the sites of the test centres, the possibility of unmasking the "blind" are of withdrawing from the trial were correctly understood in 75 to 90% of cases. The global average comprehension score was 8.7.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

[A case report of Russel's diencephalic cachexia].

The case of an infant admitted for evaluation of severe emaciation with intermittent ocular anomalies including strabismus and nystagmus is reported. This case demonstrates the value of magnetic resonance imaging and transfontanellar ultrasonography for the diagnosis of diencephalic syndrome of infancy. The prognosis of this condition is usually grim, in particular because of the severe emaciation which is disproportionate with the tumour spread. Pathophysiologic hypotheses put forward to explain this cachexia are reviewed. Although cytokines such as TNF alpha are currently incriminated in the pathophysiology of cachexia induced by a number of conditions, they have not yet been studied in diencephalic syndrome of infancy. TNF alpha is a potent lipolytic agent. Excessive production of TNF alpha may be involved in the genesis of the emaciation characteristic of diencephalic syndrome. Inappropriate production of TNF alpha may respond to the administration of specific anti-TNF monoclonal antibodies. This approach may be considered as a means for treating emaciation in patients with diencephalic syndrome of infancy.

Astrocytoma↗

Comparison of response rates to the angiotensin-converting enzyme inhibitor ramipril in mild-to-moderate hypertension in a double-blind, parallel-group study and an open single-blind study.

Appropriate clinical trial methodologies in general practice and suitable end points for dose-finding studies are discussed with reference to antihypertensive drugs in general and angiotensin-converting enzyme (ACE) inhibitors in particular. Two clinical studies were conducted with ramipril, a new nonsulfhydryl ACE inhibitor, to identify the minimum effective dose for the management of mild-to-moderate hypertension. Study 1 was a double-blind, parallel-group, randomized design with three treatment groups (placebo and 2.5 and 5 mg of ramipril), and study 2 was an open, single-blind design with individual dose titration from 2.5 to 5 mg of ramipril if the diastolic blood pressure (DBP) was greater than 90 mm Hg after 3 weeks. Response rates and DBP reductions with 2.5 mg of ramipril were similar in both studies, although overall response rates, DBP reductions, and side effect incidence appeared to be greater in the open, single-blind, dose-titration study. It is concluded that study methodology apparently influences efficacy and tolerability.

Angiotensin-Converting Enzyme Inhibitors↗

[Value of a new fast CK-MB determination for the diagnosis of myocardial infarction during the 1st hours. Preliminary study].

This study evaluated the time for a new, rapid and reliable CK-MB analysis to become positive in myocardial infarction and compared it with classical total CK analyses. Serial analyses of total CK and CK-MB were performed in 49 consecutive patients referred to the Coronary Care Unit for suspected acute myocardial infarction. Twenty of these patients had myocardial infarction with rising enzyme levels, which enabled comparison of the precocity of one analysis compared to another. In these patients, the CK-MB analysis became positive on average 85 to 110 minutes before that of total CK. This result shows that CK-MB analysis can be a diagnostic sign of acute myocardial infarction at an earlier stage than the total CK analysis. The authors discuss the clinical value of this test in difficult indications of fibrinolytic therapy and underline that it enables a more objective assessment of the time of onset of necrosis than clinical data alone.

Creatine Kinase↗

Private hospital and phase I.

Since December 1988. French law has authorized phase I studies and the creation of phase I units within public or private hospitals. The scientific standards regarding private hospitals are not different from those in public hospitals. Practitioners who conduct clinical trials in private hospitals are well aware of good clinical practices and methodological constraints. Phase I units can be structured in private as well as within public hospitals. Finally, the question to be addressed is whether clinical pharmacology and scientific investigations in healthy volunteers should be integrated in the policy of private hospitals.

Drug Evaluation↗

Coronary-to-bronchial artery anastomosis complicated with myocardial infarction.

A patient with bronchiectasis had an inferolateral myocardial infarction. Coronary arteriography revealed a large anastomosis from the left circumflex artery to the left lower lobe bronchial arteries. The relationship between the patient's myocardial infarction and possible "coronary steal" is discussed.

Bronchial Arteries↗

[Value of transcutaneous blood gas monitoring in fiberoptic bronchoscopy in intensive care patients].

Transcutaneous carbon dioxide and oxygen tensions (PtcCO2 and PtcO2) were monitored in seven critically ill patients under mechanical ventilation during fiberoptic bronchoscopy. In these conditions, both PtcO2 and PaO2 and PtcCO2 and PaCO2 correlated, with correlation coefficients of 0.964 and 0.793 respectively. Fiberoptic bronchoscopy induced an average fall in PtcO2 of 42 +/- 2.57 mmHg and an average increase in PtcCO2 of 12.1 +/- 1.89 mmHg; these two parameters returned quickly to their initial values after the procedure. Holter monitoring showed an arrhythmia in five of the seven patients. Continuous measurement of PtcO2 and PtcCO2 was a safe and reliable method for monitoring mechanically ventilated patients undergoing fiberoptic bronchoscopy.

Aged↗

Percutaneous transvenous caval interruption with the "LGM" filter: early results of a multicenter trial.

From September 1985 to December 1986, 100 patients undergoing percutaneous placement of a transvenous "LGM" caval filter were included in a multicenter prospective trial. Peripheral venograms completed by pulmonary arteriography or scintigraphy were obtained for all patients. Eighty-five patients had experienced pulmonary embolism, 59 had iliocaval thrombosis, while 40 had venous thrombosis confined to the lower limbs. In two instances, insertion or passage of the catheter was impossible. Ninety-eight "LGM" filters were placed percutaneously through the internal jugular vein, 82 of which were correctly positioned in the infrarenal inferior vena cava. Eight filters were positioned with a tilt of more than 15 degrees with respect to the vertical axis, five failed to open correctly, and three were incompletely open and tilted. No postoperative deaths were observed; there were two recurrent embolisms, and seven caval thromboses occurred during the year that followed insertion of the filter. The "user-friendliness" and efficacy of this percutaneous filter makes it a treatment of choice in the partial interruption of the inferior vena cava.

Aged↗

[Clinical effectiveness of trimetazidine in stable effort angina. A double-blind versus placebo controlled study].

The antianginal activity of trimetazidine was evaluated in a double-blind, multicentric, drug-versus-placebo study. The 32 male patients who entered the study (mean age 59.5 years) were suffering from stable angina pectoris. The stability of angina was tested by two exercise tests performed at the beginning and at the end of a two-week preselection period with placebo. The patients received 3 tablets daily of either trimetazidine (20 mg per tablet) or placebo for one month. At the end of treatment, they underwent a third exercise test. A Mann and Whitney test, used to compare the result of pre- and post-treatment exercise tests, showed a statistically significant improvement with trimetazidine as compared with the placebo for the following parameters: total work went from 4.200 +/- 372 to 5.620 +/- 387 kpm with trimetazidine and from 4.191 +/- 399 to 4.564 +/- 431 kpm with the placebo (P = 0.012); duration of exercise from 10.2 +/- 0.5 to 12.1 +/- 0.5 min with trimetazidine and from 10.2 +/- 0.5 to 10.7 +/- 0.5 min with the placebo (P = 0.016); time to 1 mm ST segment depression from 8.3 +/- 0.6 to 9.8 +/- 0.5 min with trimetazidine and from 8.4 +/- 0.5 to 9 +/- 0.7 min with the placebo (P = 0.034). These results showed that the ischaemic threshold receded with trimetazidine, while the peripheral haemodynamic parameters were not significantly changed, either at rest or during exercise. Thus, trimetazidine does not act through a chronotropic or vasodilator mechanism but through cellular regulation mechanism.

Adult↗